Trevena Inc (TRVN) gains 3.90% for July 21

Equities Staff  |

Trevena Inc (NASDAQ: TRVN) shares gained 3.90%, or $0.06 per share, to close Wednesday at $1.60. After opening the day at $1.56, shares of Trevena fluctuated between $1.60 and $1.54. 952,743 shares traded hands a decrease from their 30 day average of 3,174,378. Wednesday's activity brought Trevena’s market cap to $263,214,141.

Trevena is headquartered in Chesterbrook, Pennsylvania..

About Trevena Inc

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated inadults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new approach to treating a variety of CNS disorders.

Visit Trevena Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Trevena Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Trevena Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content